"Promising Results: Ozempic and Wegovy Show Potential in Reducing Dementia Risk, Human Trials Progressing"

Ozempic and Wegovy, weight loss drugs containing semaglutide, may reduce the risk of dementia, according to a study on mice. Researchers found that mice treated with semaglutide showed improvements in learning and memory, as well as a decrease in plaques associated with Alzheimer's disease. Clinical trials on humans are also underway to test the drug's potential in reducing dementia-related protein levels and inflammation. However, concerns about long-term side effects and the need for further testing remain. Obesity itself is a risk factor for dementia, and weight loss can help lower the risk.